ABSTRACT
The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.
Subject(s)
Antibodies, Viral/blood , COVID-19 Vaccines/immunology , COVID-19/diagnostic imaging , COVID-19/immunology , SARS-CoV-2/immunology , Vaccination/adverse effects , Brazil , COVID-19/prevention & control , COVID-19 Nucleic Acid Testing , COVID-19 Vaccines/administration & dosage , Clinical Trials as Topic , Dexamethasone/therapeutic use , Humans , Male , Middle Aged , SARS-CoV-2/genetics , Severity of Illness Index , Tomography, X-Ray Computed , Treatment Outcome , Vaccination/statistics & numerical data , COVID-19 Drug TreatmentABSTRACT
Herein, we report a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and dengue coinfection, presented as a fatal stroke in our hospital, in São José do Rio Preto, São Paulo State, a Brazilian city hyperendemic for dengue viruses and other arthropod-borne viruses (arboviruses) and currently facing a surge of SARS-CoV-2 cases. This case is the first described in the literature and contributes to the better understanding of clinical presentations of two important diseases in a tropical setting.